Alvotech fundraises $300m to bolster biosimilar development

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Sitthiphong)
(Image: Getty/Sitthiphong)

Related tags Biosimilars development Manufacturing Biologics facility Investment equity

Alvotech raised $300m through a private bond offering and is set to use the earnings to continue the growth of its biosimilar pipeline.

The company’s current product pipeline consists of six biosimilar monoclonal antibodies for the treatment of cancer, autoimmune diseases, and inflammatory diseases.

In a statement, Robert Wessmen, founder of Alvotech said that the $300m (€263m) financing transaction will help fund the company’s plans for future growth – securing the financing of biosimilar development, and clinical studies.

He further said that results of this development will “bring significant potential for healthcare providers around the world to drive healthcare savings and expand patient access to high-quality biosimilars.”

Biosimilar production and development will occur at the company’s new manufacturing facility​ in Reykjavik, Iceland. The facility was a $250m investment by the company in 2013.

Alvotech stated that it has worked to develop itself into a fully integrated biopharmaceutical company with capabilities in cell line development of biosimilars, manufacturing, clinical development, and registrations.

Additional agreements

Aside from the recent fundraising efforts of Alvotech, Japan-based Fuji Pharma will acquire 4.2% equity in the company as of January 2019.

This equity acquisition came after the two companies entered a partnership agreement to further expand Alvotech’s presence in the Asia-Pacific region. Through this partnership, Alvotech will be able to commercialize its biosimilar pipeline in Japan.

Additionally, in September 2018, Alvotech entered a joint-venture agreement with Changchun High & New Technology Industries – the arrangement was valued at $200m. The collaboration will see the creation of a biologics drugs manufacturing facility in Changchun, China. 

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us

Products

View more

Webinars